Capital Cell
VC Fund
Barcelona, Spain
Capital Cell is a crowdinvesting platform for biotech and life sciences companies. Mixing VC, business angels, accredited investors, and the power of the crowd, the company is building a global meeting point for companies and researchers working, fostering, and financing tomorrow’s medical science.
- Total investments:
- 52
- Last investment:
- Lead investor:
- 27%
Last updated:
For AI agents: llms.txt
Industries Capital Cell invests in
Stages Capital Cell invests in
Countries Capital Cell invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
1 more contact available
Round size
- Seed
- $384k–$1.9M
- Series A
- $1.1M–$21M
- Equity Crowdfunding
- $137k–$1.5M
Investment Focus
Industry
- Health Care 31 (60%)
- Biotechnology 24 (46%)
- Medical 18 (35%)
- Medical Device 17 (33%)
- Pharmaceutical 13 (25%)
Stage
- Equity Crowdfunding 25 (48%)
- Seed 8 (15%)
- Series A 5 (10%)
- Venture - Series Unknown 4 (8%)
- Pre-Seed 3 (6%)
Country
- Spain 33 (63%)
- France 3 (6%)
- United States 3 (6%)
- United Kingdom 3 (6%)
- Switzerland 2 (4%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Daniel Oliver
Director
|
Director | Total investments: 1 | Find email | |
Joan Marcos
General Manager
|
General Manager | Total investments: 1 | Find email | |
Patrick O'Brien
Investment Manager
|
Investment Manager | Total investments: 0 | Find email | |
Patrick O'Brien
Investment Manager
|
Investment Manager | Total investments: 1 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
DYNAMICS VR
|
Dynamics VR provides rehab software for clinics to tackle musculoskeletal pain and movement impairments caused by brain trauma. | $1.5M / Seed / Mar 03, 2026 | |
EVis Bioscience
|
EVis Bioscience offers gene delivery solutions using extracellular vesicles, lipid nanoparticles, and hybrid systems. | $872.7K / Pre-Seed / Feb 23, 2026 | |
Axoltis Pharma
|
Axoltis Pharma is a biotech company that develops drugs for degenerative and traumatic neurological disorders. | $20.9M / Series A / Dec 02, 2025 | |
EVerZom
|
EVerZom is a nanomedicine biotech company providing a large scale of GMP manufacturing platform of extracellular vesicles. They develop a bioproduction platform to produce extracellular vesicles at a commercial scale in a GMP compliant way for pharmaceutical companies with applications in regenerative medicine and drug delivery. Extracellularvesicles that encompass exosomes, microvesicles, and apoptotic bodies are the tools used by cells to communicate with each other. EVerZom was founded in 2019 and is headquartered in Paris, Ile-de-France, France. | $11.6M / Series A / Oct 14, 2025 | |
MgShell
|
MgShell offers intraocular devices for the treatment of age-related macular degeneration and other ocular diseases. Their technology is the only technical solution capable of replicating current clinical practice with a single injection and releasing the same therapeutic drug doses at predetermined periods, autonomously and without surgicalprocedures. | $1.3M / Seed / Apr 30, 2025 | |
MSInsight
|
MSInsight bioinformatics start-up that develops diagnostic and treatment response prediction solutions for Microsatellite Instability (MSI) cancers. Its service offering focuses on diagnostic and prognostic biomarkers of treatment response for MSI tumors. | $1.7M / Seed / Mar 10, 2025 | |
OxyPrem
|
OxyPrem is an advanced oxygen sensor that continuously monitors oxygen levels in the brains of high-risk preterm infants. The company develops, designs, and manufactures sensor solutions for monitoring of preterm infants. It is a reusable device that offers better clinical care due to its high quality, while substantially reducing waste.OxyPremuses harmless light (more on NIRS) to determine absolute hemoglobin oxygen saturation in any human tissue. It helps them to prevent early death and severe long-term brain damage to this most vulnerable group of patients. | $3.2M / Equity Crowdfunding / Aug 30, 2024 | |
Affirma Biotech
|
Affirma Biotech is a developer of host-directed drugs as broad-spectrum treatments for chronic and severe infectious diseases. The company utilizes host-directed therapy strategies to interfere with host cell factors that are required by a pathogen for replication or persistence. The company engages in the discovery and development of newanti-infective drugs via immunomodulation. | $1.9M / Venture - Series Unknown / Feb 01, 2024 | |
MediQuo
|
MediQuo is a hospital in your pocket, connecting patients and professionals for any health interaction. Healthcare today has 75% of unnecessary medical visits that could be taken in the distance, and the vast majority of health professionals are using messaging platforms such as WhatsApp to communicate with patients or other health professionals.MediQuo is a chat-based app specialised in health, GDPR and health data compliant, giving professionals time control, incorporating patient medical history and phone privacy. Allowing also video and audio communication. It is a place for discussion, appointments or medical consultation with your doctor or any new health professional. Also includes immediate 24/7 medical response and a network, for health information and professional discovery. We have done already 1M consultations and got 600k app downloads. Our Google Play Ratings are 4,6 (with 6k reviews). We are amongst the top health apps in Spain and Latam. | $1.5M / Venture - Series Unknown / Apr 14, 2023 | |
Loop Dx
|
Loop Dx is developing point-of-care diagnostics for faster detection of sepsis to reduce sepsis mortality, patient side effects, and antibiotic resistance due to unnecessary provided antibiotics. We want to facilitate healthcare providers the tools they need for faster sepsis identification saving lives and optimizing sepsis management. | $802.9K / Seed / Jan 01, 2023 | |
| See all 52 investments → | |||
Co-Investors
Ship2B
3 deals together
ENISA
3 deals together
Inveready
2 deals together
O2h Ventures
1 deal together
Agile Capital
1 deal together
Axon Partners Group
1 deal together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Capital Cell invest in?
Capital Cell invests primarily in Health Care, Biotechnology and Medical startups, most often at Equity Crowdfunding and Seed stage. Most of the 52 investments tracked by Shizune back companies in Spain. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Capital Cell's check size?
Capital Cell typically joins rounds of $384k–$1.9M at Seed, $1.1M–$21M at Series A and $137k–$1.5M at Equity Crowdfunding. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Capital Cell participates in.
How do I contact Capital Cell?
Public channels for Capital Cell include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Capital Cell?
The team at Capital Cell includes Daniel Oliver (Director), Joan Marcos (General Manager) and Patrick O'Brien (Investment Manager). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
